"The big three" infections AIDS, TB and malaria have caught the world's attention but other disabling and fatal infectious diseases in Africa are being ignored, say three eminent tropical disease researchers in the international health journal PLoS Medicine.
The neglected tropical diseases, which include sleeping sickness, schistosomiasis, river blindness, hookworm, elephantiasis, and blinding trachoma, affect several hundred million people, and kill at least half a million annually, and yet they garner little attention from donors, policymakers, and public health officials.
The researchers, led by Professor David Molyneux, Director of the Lymphatic Filariasis Support Centre at the Liverpool School of Tropical Medicine, argue that a "rapid impact package" distribution of four anti-parasitic drugs across Africa to treat seven neglected diseases "would bring tangible benefits to the world's" poorest communities.
The cost of the package, they say, would be negligible, a mere 40 cents per person per year, compared with a minimum of $200 per person per year to treat HIV/AIDS, $200 to treat a single episode of TB, and $7-10 to treat a single episode of malaria.
Three of the drugs in the package (ivermectin, azithromycin, and albendazole) are being donated by their manufacturers, and the fourth (praziquantel) now costs only 7 cents per tablet.
Professor Molyneux and his colleagues, Professor Peter Hotez of the Human Hookworm Initiative and Professor Alan Fenwick of the Schistosomiasis Control Initiative, argue that a rapid impact package against some of the neglected tropical diseases could permanently reduce their incidence.